Related Experiment Videos
Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results
C Milanese1, L La Mantia, A Salmaggi
1Istituto Neurologico, C. Besta, Milano.
Italian Journal of Neurological Sciences
|February 1, 1988
Summary
Azathioprine significantly slowed Multiple Sclerosis progression in a 3-year trial. This immunomodulator showed benefits compared to placebo, without impacting relapse rates.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Current treatments aim to reduce disease activity and manage symptoms.
- Identifying effective long-term therapies for MS progression remains a priority.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Azathioprine in patients with Multiple Sclerosis.
- To assess the impact of Azathioprine on disease progression and relapse rates over time.
Main Methods:
- A double-blind, placebo-controlled, prospective randomized trial was conducted.
- Thirty-eight patients diagnosed with Multiple Sclerosis participated in the study.
- Treatment groups received either Azathioprine or a placebo for an extended duration.
Main Results:
- Azathioprine treatment significantly reduced Multiple Sclerosis progression compared to placebo after three years (P < 0.025).
- The observed benefit in disease progression was independent of the clinical course of MS.
- Azathioprine did not significantly affect the relapse rate in the treated group.
Conclusions:
- Azathioprine demonstrates a significant disease-modifying effect in Multiple Sclerosis, particularly evident after prolonged treatment.
- The findings suggest Azathioprine is a viable option for slowing MS progression, though its effect on relapse rates requires further investigation.